CASI Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . CASI Pharmaceuticals
CASI Stock  USD 1.30  0.22  14.47%   
CASI Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CASI Pharmaceuticals' valuation are provided below:
Gross Profit
13 M
Profit Margin
(1.29)
Market Capitalization
23.5 M
Enterprise Value Revenue
0.9354
Revenue
31.4 M
We have found one hundred twenty available fundamental signals for CASI Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of CASI Pharmaceuticals prevailing fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 107.3 M. Enterprise Value is estimated to decrease to about 89.9 M

CASI Pharmaceuticals Total Revenue

29.96 Million

Check CASI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CASI Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 795.3 K, Selling General Administrative of 24.8 M or Other Operating Expenses of 71.6 M, as well as many indicators such as Price To Sales Ratio of 1.45, Dividend Yield of 0.0106 or PTB Ratio of 22.28. CASI financial statements analysis is a perfect complement when working with CASI Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with CASI Stock
Check out the analysis of CASI Pharmaceuticals Correlation against competitors.
For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.

CASI Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding16.1 M15.3 M7.8 M
Slightly volatile
Total Assets49.2 M53.7 M54.7 M
Slightly volatile
Total Current Liabilities38.3 M36.5 M9.5 M
Slightly volatile
Property Plant And Equipment Net11.9 M11.4 M5.9 M
Slightly volatile
Accounts Payable2.7 M2.7 M2.1 M
Slightly volatile
Cash12.8 M13.5 M27.2 M
Slightly volatile
Non Current Assets Total9.9 M13.9 M16.1 M
Slightly volatile
Cash And Short Term Investments32.1 M16.1 M31 M
Slightly volatile
Common Stock Total Equity1.7 M1.6 M833.7 K
Slightly volatile
Liabilities And Stockholders Equity49.2 M53.7 M54.7 M
Slightly volatile
Other Stockholder Equity396.2 M703.7 M500.2 M
Slightly volatile
Total Liabilities54.4 M51.8 M18.4 M
Slightly volatile
Property Plant And Equipment Gross17.9 M17.1 M6.5 M
Slightly volatile
Total Current Assets39.3 M39.6 M38.6 M
Slightly volatile
Common Stock1.9 K2 K453.1 K
Very volatile
Short and Long Term Debt Total23.2 M22.1 M5.6 M
Slightly volatile
Other Current Liabilities12.2 M11.6 M4.1 M
Slightly volatile
Net Receivables16.1 M15.3 M4.7 M
Slightly volatile
Non Current Liabilities Total16.1 M15.4 M11 M
Slightly volatile
Other Current Assets2.3 M2.9 M3 M
Pretty Stable
Short Term Debt20.6 M19.6 M3.8 M
Slightly volatile
Other Assets215.2 K226.6 K2.7 M
Pretty Stable
Property Plant Equipment26.6 M25.3 M8.6 M
Slightly volatile
Current Deferred Revenue1.7 M2.5 M1.6 M
Slightly volatile
Other Liabilities20.8 M19.8 M9.3 M
Slightly volatile
Capital Surpluse571.4 M799 M554.7 M
Slightly volatile
Long Term Debt Total1.6 M1.7 M1.5 M
Slightly volatile
Short and Long Term Debt22.2 M21.1 M7.1 M
Slightly volatile
Net Invested Capital19.2 M20.2 M49.9 M
Very volatile
Net Working Capital3 M3.1 M42 M
Pretty Stable
Capital Stock1.9 K2 K762.9 K
Slightly volatile
Capital Lease Obligations2.5 M3.8 M2.3 M
Pretty Stable
Long Term Investments1.6 M1.7 M13.9 M
Pretty Stable

CASI Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative24.8 M23.6 M13.1 M
Slightly volatile
Other Operating Expenses71.6 M68.2 M31.5 M
Slightly volatile
Total Operating Expenses26 M50.8 M24.1 M
Slightly volatile
Depreciation And Amortization2.4 M2.3 M1.3 M
Slightly volatile
Research Development10.7 M8.9 M7.4 M
Slightly volatile
Non Recurring7.2 M5.9 M9.2 M
Slightly volatile
Interest Income460.2 K539 K307.1 K
Slightly volatile
Reconciled Depreciation2.4 M2.3 M1.3 M
Slightly volatile
Selling And Marketing Expenses13.6 M17.9 M7.2 M
Slightly volatile

CASI Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow23.2 M17.1 M32.5 M
Pretty Stable
Depreciation2.4 M2.3 M1.2 M
Slightly volatile
Capital Expenditures228 K240 K5.1 M
Slightly volatile
End Period Cash Flow12.8 M13.5 M32.5 M
Very volatile
Stock Based Compensation1.2 M1.3 M3.6 M
Slightly volatile
Change To Netincome9.3 M9 M7.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.451.5213781
Slightly volatile
Dividend Yield0.01060.01490.0157
Very volatile
Days Sales Outstanding339196268
Slightly volatile
Average Payables751.5 K791 K803.5 K
Pretty Stable
Stock Based Compensation To Revenue0.04350.045814.1875
Slightly volatile
Capex To Depreciation0.09780.1034.7519
Pretty Stable
Inventory Turnover4.273.31134.9146
Slightly volatile
Days Of Inventory On Hand144110119
Slightly volatile
Payables Turnover6.716.38672.5784
Pretty Stable
Sales General And Administrative To Revenue0.780.826227.2771
Slightly volatile
Research And Ddevelopement To Revenue0.30.312523.5367
Slightly volatile
Capex To Revenue0.0080.00843.4866
Slightly volatile
Cash Per Share1.01.0493.8762
Very volatile
Days Payables Outstanding54.2957.1510.1 K
Slightly volatile
Income Quality0.870.74440.6525
Pretty Stable
Intangibles To Total Assets0.00420.00440.1182
Slightly volatile
Current Ratio1.031.08579.159
Slightly volatile
Receivables Turnover3.671.85972.8364
Slightly volatile
Capex Per Share0.01490.01560.5475
Pretty Stable
Average Receivables13 K13.6 K225 K
Slightly volatile
Revenue Per Share1.771.86031.0546
Slightly volatile
Interest Debt Per Share1.431.50011.2565
Pretty Stable
Debt To Assets0.430.41250.1159
Slightly volatile
Operating Cycle383306332
Slightly volatile
Days Of Payables Outstanding54.2957.1510.1 K
Slightly volatile
Quick Ratio0.890.94168.9994
Slightly volatile
Cash Ratio0.350.36958.0143
Slightly volatile
Days Of Inventory Outstanding144110119
Slightly volatile
Days Of Sales Outstanding336196220
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.91.00821.2149
Pretty Stable
Fixed Asset Turnover2.392.51216.7302
Slightly volatile
Debt Ratio0.430.41250.1159
Slightly volatile
Price Sales Ratio1.451.5213781
Slightly volatile
Asset Turnover0.560.53170.2054
Slightly volatile

CASI Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap107.3 M110 M47.7 M
Pretty Stable

CASI Fundamental Market Drivers

Cash And Short Term Investments16.1 M

CASI Upcoming Events

24th of April 2024
Upcoming Quarterly Report
View
15th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
24th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About CASI Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as CASI Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although CASI Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue2.5 M1.7 M
Total Revenue28.5 M30 M
Cost Of Revenue17.4 M10.1 M
Stock Based Compensation To Revenue 0.05  0.04 
Sales General And Administrative To Revenue 0.83  0.78 
Research And Ddevelopement To Revenue 0.31  0.30 
Capex To Revenue 0.01  0.01 
Revenue Per Share 1.86  1.77 
Ebit Per Revenue(1.39)(1.32)

Currently Active Assets on Macroaxis

USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option
BCATBlackRock Capital Allocation
PDIPimco Dynamic Income
When determining whether CASI Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CASI Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Casi Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Casi Pharmaceuticals Stock:
How To Invest In CASI
Details
Is CASI Stock a good investment?
Details
What is CASI Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of CASI Pharmaceuticals Correlation against competitors.
For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.54)
Revenue Per Share
1.977
Quarterly Revenue Growth
0.83
Return On Assets
(0.51)
Return On Equity
(10.95)
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if CASI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY